Hydroxyurea use in patients with sickle cell disease in a Medicaid population

American Journal of Hematology

Volumn 86, Issue 10, 2011, Pages 888-890

  Ritho, Jane ^a   Liu, Huazhi ^a   Hartzema, Abraham G ^a   Lottenberg, Richard ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; HYDROXYUREA;

ADOLESCENT; ADULT; COHORT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; GENOTYPE; HOSPITALIZATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAID; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; TREATMENT DURATION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; COHORT STUDIES; FEMALE; FLORIDA; HUMANS; HYDROXYUREA; MALE; MEDICAID; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 80052872584     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22134     Document Type: Letter

References (13)

1. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the Treatment of Sickle Cell Disease. Evidence Report/Technology Assessment No. 165. Johns Hopkins University Evidence based Practice Center under contract No. 290-02-0018, AHRQ Publication No. 08-E007, Rockville, MD.
2. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
3. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in sickle cell anemia. Am J Hematol. 2000; 64: 26-31.
4. Steinberg MH, Barton F, Castro O, et al. Effects of hydroxyurea on morbidity and mortality in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
5. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in sickle cell anemia and msh patients' follow-up. Am J Hematol 2010; 85: 403-408.
6. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institute of Health consensus development conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148: 932-938.
7. Lanzkron S, Haywood CJr, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006; 81: 927-932.
8. Lanzkron S, Haywood C, Fagan PJ et al. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved 2010; 21: 1114-1123.
9. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880-2883.
10. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60: 657-665.
11. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86: 273-277.
12. Kauf, TL, Coates, TD, Huazhi, L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84: 323-327.
13. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 449-457.